DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Bethesda North Marriott Hotel and Conference Center

2018年4月23日 (月) 午後 1:00 - 2018年4月25日 (水) 午後 4:15

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Biostatistics Industry and Regulator Forum

Session 4: Bridging the Gap: RWE and RCT

Session Chair(s)

Frank W. Rockhold, PhD, MSc

Frank W. Rockhold, PhD, MSc

Professor of Biostatistics

Duke Clinical Research Institute, Duke University Medical Center, United States

Mark  Levenson, PhD

Mark Levenson, PhD

Director, Division of Biometrics VII, Office of Biostatistics, OT, CDER

FDA, United States

There is currently a drive and energy behind the use of “big data” and “real world data”. There are three main motivations: Use of RWE data are viewed as 1) a quicker and less expensive approach to clinical development, 2) a way to answer questions of how treatments are or will be used in the real world, and 3) where randomized trials are not ethically possible. We will restrict the discussion to studies done post approval of the first indication as “RWE” is a non-sequitur for an unapproved drug. One of the current issues is the blurring in the use if RWE to answer scientific and medically important questions and if RWE is somehow distinct from the conduct randomized trials and only used to do observational studies. In this sense, the debate is often posed as “should I do a RWE study OR a clinical trial” or “how can I show that an Obs study will yield the same answer as a RCT”. The truth for drug development is the this should be an “and” discussion not an “or” discussion as both approaches can be valuable. In addition, should more care should be given not to avoid the concept of randomization too quickly in the use of RWE as there many techniques allow us to bridge that gap?

Learning Objective : At the conclusion of this session, participants should be able to:
  • Recognize the circumstances when randomized trials and observational studies are appropriate to address clinical questions
  • Recognize the opportunities and challenges of pragmatic and clustered trials
  • Discuss the important issues when considering an observational study

Speaker(s)

Frank W. Rockhold, PhD, MSc

Randomized Pragmatic Clinical Trials: A Potential Bridge Between ”RCTs” and “RWE” Studies?

Frank W. Rockhold, PhD, MSc

Duke Clinical Research Institute, Duke University Medical Center, United States

Professor of Biostatistics

Hrishikesh  Chakraborty

Statistical Considerations for Pragmatic Cluster Randomized Trial Design

Hrishikesh Chakraborty

DCRI, Duke University, United States

Associate Director

Douglas E Faries, PhD

Bridging the Gap: Better Use of RWE for Decision-Making from an Industry Perspective

Douglas E Faries, PhD

Eli Lilly and Company, United States

Research Fellow, Global Statistical Sciences

Jessica  Franklin, PhD

Using Healthcare Databases To Evaluate The Safety And Effectiveness Of Newly Marketed Medications

Jessica Franklin, PhD

Optum, United States

Principal Consultant, Epidemiology and Real-World Evidence

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。